MPEP § 2412.02 — Definition of “Sequence Listing XML” (Annotated Rules)
§2412.02 Definition of “Sequence Listing XML”
This page consolidates and annotates all enforceable requirements under MPEP § 2412.02, including statutory authority, regulatory rules, examiner guidance, and practice notes. It is provided as guidance, with links to the ground truth sources. This is information only, it is not legal advice.
Definition of “Sequence Listing XML”
This section addresses Definition of “Sequence Listing XML”. Primary authority: 35 U.S.C. 111, 37 CFR 1.831, and 37 CFR 1.821(c). Contains: 1 requirement and 1 other statement.
Key Rules
Sequence Listing Content
[Editor Note: This section is applicable to all applications with a filing date, or, for national phase applications, an international filing date, on or after July 1, 2022, having disclosure of one or more nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).]
(a) Patent applications disclosing a nucleotide and/or amino acid sequences by enumeration of its residues, as defined in paragraph (b) of this section, must contain, as a separate part of the disclosure, a computer readable Sequence Listing in XML format (a “Sequence Listing XML”). Disclosed nucleotide or amino acid sequences that do not meet the definition in paragraph (b) of this section must not be included in the “Sequence Listing XML.” The “Sequence Listing XML” contains the information of the nucleotide and/or amino acid sequence(s) disclosed in the patent application using the symbols and format in accordance with the requirements of §§ 1.832 through 1.834.
(a) Patent applications disclosing a nucleotide and/or amino acid sequences by enumeration of its residues, as defined in paragraph (b) of this section, must contain, as a separate part of the disclosure, a computer readable Sequence Listing in XML format (a “Sequence Listing XML”). Disclosed nucleotide or amino acid sequences that do not meet the definition in paragraph (b) of this section must not be included in the “Sequence Listing XML.” The “Sequence Listing XML” contains the information of the nucleotide and/or amino acid sequence(s) disclosed in the patent application using the symbols and format in accordance with the requirements of §§ 1.832 through 1.834.
(a) Patent applications disclosing a nucleotide and/or amino acid sequences by enumeration of its residues, as defined in paragraph (b) of this section, must contain, as a separate part of the disclosure, a computer readable Sequence Listing in XML format (a “Sequence Listing XML”). Disclosed nucleotide or amino acid sequences that do not meet the definition in paragraph (b) of this section must not be included in the “Sequence Listing XML.” The “Sequence Listing XML” contains the information of the nucleotide and/or amino acid sequence(s) disclosed in the patent application using the symbols and format in accordance with the requirements of §§ 1.832 through 1.834.
For 35 U.S.C. 111 applications and international applications filed on or after July 1, 2022, that disclose one or more nucleotide and/or amino acid sequences as enumerated by its residues, each nucleotide and/or amino acid sequence and associated sequence data must be presented as a separate part of the disclosure that comprises the sequences in computer readable XML format in accordance with WIPO Standard ST.26 as implemented by 37 CFR 1.831 – 1.834. This sequence listing is referred to as a “Sequence Listing XML” in order to distinguish it from a “Sequence Listing” submitted in an application having a filing date BEFORE July 1, 2022. For 35 U.S.C. 111 applications and international applications having a filing date before July 1, 2022, that disclose of nucleotide and/or amino acid sequences, see 37 CFR 1.821(c) and 1.821(e)(1). See also MPEP §§ 2421.01 and 2421.02.
For 35 U.S.C. 111 applications and international applications filed on or after July 1, 2022, that disclose one or more nucleotide and/or amino acid sequences as enumerated by its residues, each nucleotide and/or amino acid sequence and associated sequence data must be presented as a separate part of the disclosure that comprises the sequences in computer readable XML format in accordance with WIPO Standard ST.26 as implemented by 37 CFR 1.831 – 1.834. This sequence listing is referred to as a “Sequence Listing XML” in order to distinguish it from a “Sequence Listing” submitted in an application having a filing date BEFORE July 1, 2022. For 35 U.S.C. 111 applications and international applications having a filing date before July 1, 2022, that disclose of nucleotide and/or amino acid sequences, see 37 CFR 1.821(c) and 1.821(e)(1). See also MPEP §§ 2421.01 and 2421.02.
Citations
| Primary topic | Citation |
|---|---|
| Sequence Listing Content | 35 U.S.C. § 111 |
| Sequence Listing Content | 37 CFR § 1.821(c) |
| Sequence Listing Content | 37 CFR § 1.831 |
| Sequence Listing Content | 37 CFR § 1.831(b) |
| Sequence Listing Content | 37 CFR § 1.832 |
| Sequence Listing Content | MPEP § 2421.01 |
Source Text from USPTO’s MPEP
This is an exact copy of the MPEP from the USPTO. It is here for your reference to see the section in context.
Official MPEP § 2412.02 — Definition of “Sequence Listing XML”
Source: USPTO2412.02 Definition of “Sequence Listing XML” [R-01.2024]
[Editor Note: This section is applicable to all applications with a filing date, or, for national phase applications, an international filing date, on or after July 1, 2022, having disclosure of one or more nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).]
37 CFR 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures.
- (a) Patent applications disclosing a nucleotide and/or amino acid sequences by enumeration of its residues, as defined in paragraph (b) of this section, must contain, as a separate part of the disclosure, a computer readable Sequence Listing in XML format (a “Sequence Listing XML”). Disclosed nucleotide or amino acid sequences that do not meet the definition in paragraph (b) of this section must not be included in the “Sequence Listing XML.” The “Sequence Listing XML” contains the information of the nucleotide and/or amino acid sequence(s) disclosed in the patent application using the symbols and format in accordance with the requirements of §§ 1.832 through 1.834.
-
*****
For 35 U.S.C. 111 applications and international applications filed on or after July 1, 2022, that disclose one or more nucleotide and/or amino acid sequences as enumerated by its residues, each nucleotide and/or amino acid sequence and associated sequence data must be presented as a separate part of the disclosure that comprises the sequences in computer readable XML format in accordance with WIPO Standard ST.26 as implemented by 37 CFR 1.831 – 1.834. This sequence listing is referred to as a “Sequence Listing XML” in order to distinguish it from a “Sequence Listing” submitted in an application having a filing date BEFORE July 1, 2022. For 35 U.S.C. 111 applications and international applications having a filing date before July 1, 2022, that disclose of nucleotide and/or amino acid sequences, see 37 CFR 1.821(c) and 1.821(e)(1). See also MPEP §§ 2421.01 and 2421.02.